OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice
Rujul H Parikh, Sagar Lonial
CA A Cancer Journal for Clinicians (2023) Vol. 73, Iss. 3, pp. 275-285
Open Access | Times Cited: 66
Rujul H Parikh, Sagar Lonial
CA A Cancer Journal for Clinicians (2023) Vol. 73, Iss. 3, pp. 275-285
Open Access | Times Cited: 66
Showing 1-25 of 66 citing articles:
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
Steven Μ. Albelda
Nature Reviews Clinical Oncology (2023) Vol. 21, Iss. 1, pp. 47-66
Closed Access | Times Cited: 182
Steven Μ. Albelda
Nature Reviews Clinical Oncology (2023) Vol. 21, Iss. 1, pp. 47-66
Closed Access | Times Cited: 182
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Lu Tang, Zhongpei Huang, Heng Mei, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 59
Lu Tang, Zhongpei Huang, Heng Mei, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 59
Beyond the blood: expanding CAR T cell therapy to solid tumors
Uğur Uslu, Carl H. June
Nature Biotechnology (2024)
Closed Access | Times Cited: 20
Uğur Uslu, Carl H. June
Nature Biotechnology (2024)
Closed Access | Times Cited: 20
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Fumou Sun, Yan Cheng, Visanu Wanchai, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 17
Fumou Sun, Yan Cheng, Visanu Wanchai, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 17
Tandem CAR-T cell therapy: recent advances and current challenges
Sara Gómez-Melero, Fakhri Hassouneh, Isabel M. Vallejo-Bermúdez, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access | Times Cited: 2
Sara Gómez-Melero, Fakhri Hassouneh, Isabel M. Vallejo-Bermúdez, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access | Times Cited: 2
Decoding the role of miRNAs in multiple myeloma pathogenesis: A focus on signaling pathways
Amr Mohamed Yehia, Elsayed G.E. Elsakka, Ahmed I. Abulsoud, et al.
Pathology - Research and Practice (2023) Vol. 248, pp. 154715-154715
Closed Access | Times Cited: 32
Amr Mohamed Yehia, Elsayed G.E. Elsakka, Ahmed I. Abulsoud, et al.
Pathology - Research and Practice (2023) Vol. 248, pp. 154715-154715
Closed Access | Times Cited: 32
miRNAs driving diagnosis, progression, and drug resistance in multiple myeloma
Mohamed A. Elkady, Amr Mohamed Yehia, Elsayed G.E. Elsakka, et al.
Pathology - Research and Practice (2023) Vol. 248, pp. 154704-154704
Closed Access | Times Cited: 28
Mohamed A. Elkady, Amr Mohamed Yehia, Elsayed G.E. Elsakka, et al.
Pathology - Research and Practice (2023) Vol. 248, pp. 154704-154704
Closed Access | Times Cited: 28
Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management
Mariam Markouli, Fauzia Ullah, Serhan Ünlü, et al.
Current Oncology (2023) Vol. 30, Iss. 7, pp. 6330-6352
Open Access | Times Cited: 23
Mariam Markouli, Fauzia Ullah, Serhan Ünlü, et al.
Current Oncology (2023) Vol. 30, Iss. 7, pp. 6330-6352
Open Access | Times Cited: 23
Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies
Yuxian Huang, Yinjie Qin, Ying-Zhi He, et al.
Drug Resistance Updates (2024) Vol. 74, pp. 101082-101082
Open Access | Times Cited: 15
Yuxian Huang, Yinjie Qin, Ying-Zhi He, et al.
Drug Resistance Updates (2024) Vol. 74, pp. 101082-101082
Open Access | Times Cited: 15
The potential and promise for clinical application of adoptive T cell therapy in cancer
Yinqi Li, Yeteng Zheng, Taiqing Liu, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 12
Yinqi Li, Yeteng Zheng, Taiqing Liu, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 12
The underlying mechanism of chimeric antigen receptor (CAR)-T cell therapy triggering secondary T-cell cancers: Mystery of the Sphinx?
Zhaokai Zhou, Ge Zhang, Yudi Xu, et al.
Cancer Letters (2024) Vol. 597, pp. 217083-217083
Closed Access | Times Cited: 10
Zhaokai Zhou, Ge Zhang, Yudi Xu, et al.
Cancer Letters (2024) Vol. 597, pp. 217083-217083
Closed Access | Times Cited: 10
The power and the promise of CAR-mediated cell immunotherapy for clinical application in pancreatic cancer
Haoyu Tang, Yizhi Cao, Yiwei Zhou, et al.
Journal of Advanced Research (2024)
Open Access | Times Cited: 9
Haoyu Tang, Yizhi Cao, Yiwei Zhou, et al.
Journal of Advanced Research (2024)
Open Access | Times Cited: 9
Intratumoral Microbiota as a Target for Advanced Cancer Therapeutics
Fei Peng, Mengyuan Hu, Zhiyue Su, et al.
Advanced Materials (2024) Vol. 36, Iss. 38
Closed Access | Times Cited: 9
Fei Peng, Mengyuan Hu, Zhiyue Su, et al.
Advanced Materials (2024) Vol. 36, Iss. 38
Closed Access | Times Cited: 9
Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody
Till Braun, Michael Rade, Maximilian Merz, et al.
Nature Medicine (2025)
Closed Access | Times Cited: 1
Till Braun, Michael Rade, Maximilian Merz, et al.
Nature Medicine (2025)
Closed Access | Times Cited: 1
Andrographolide induced ferroptosis in multiple myeloma cells by regulating the P38/Nrf2/HO-1 pathway
Wenxia Li, Hangjie Fu, Liuyuan Fang, et al.
Archives of Biochemistry and Biophysics (2023) Vol. 742, pp. 109622-109622
Closed Access | Times Cited: 20
Wenxia Li, Hangjie Fu, Liuyuan Fang, et al.
Archives of Biochemistry and Biophysics (2023) Vol. 742, pp. 109622-109622
Closed Access | Times Cited: 20
A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells
Yang Liu, Xingxing Jie, Nian Li, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 18
Yang Liu, Xingxing Jie, Nian Li, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 18
Advancements in Personalized CAR-T Therapy: Comprehensive Overview of Biomarkers and Therapeutic Targets in Hematological Malignancies
Wioletta Olejarz, Karol Sadowski, Daniel Szulczyk, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7743-7743
Open Access | Times Cited: 8
Wioletta Olejarz, Karol Sadowski, Daniel Szulczyk, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7743-7743
Open Access | Times Cited: 8
Optimizing the CAR T-Cell Therapy Experience in Multiple Myeloma: Clinical Pearls From an Expert Roundtable
Sikander Ailawadhi, Leyla Shune, Sandy W. Wong, et al.
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, Iss. 5, pp. e217-e225
Open Access | Times Cited: 7
Sikander Ailawadhi, Leyla Shune, Sandy W. Wong, et al.
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, Iss. 5, pp. e217-e225
Open Access | Times Cited: 7
Ethanol extract of Eclipta prostrata induces multiple myeloma ferroptosis via Keap1/Nrf2/HO-1 axis
Wenxia Li, Xuejiao Yin, Hangjie Fu, et al.
Phytomedicine (2024) Vol. 128, pp. 155401-155401
Closed Access | Times Cited: 7
Wenxia Li, Xuejiao Yin, Hangjie Fu, et al.
Phytomedicine (2024) Vol. 128, pp. 155401-155401
Closed Access | Times Cited: 7
Progress and prospect of ASCT combined with CAR-T therapy in the treatment of multiple myeloma
S. Yuan, Ying Chen, Huasheng Liu
Therapeutic Advances in Hematology (2024) Vol. 15
Open Access | Times Cited: 7
S. Yuan, Ying Chen, Huasheng Liu
Therapeutic Advances in Hematology (2024) Vol. 15
Open Access | Times Cited: 7
IL-4 drives exhaustion of CD8+ CART cells
Carli M. Stewart, Elizabeth L. Siegler, Reona Sakemura, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
Carli M. Stewart, Elizabeth L. Siegler, Reona Sakemura, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
Selinexor: Targeting a novel pathway in multiple myeloma
Clifton C. Mo, Andrew J. Yee, Shonali Midha, et al.
eJHaem (2023) Vol. 4, Iss. 3, pp. 792-810
Open Access | Times Cited: 16
Clifton C. Mo, Andrew J. Yee, Shonali Midha, et al.
eJHaem (2023) Vol. 4, Iss. 3, pp. 792-810
Open Access | Times Cited: 16
The Impact of Outpatient versus Inpatient Administration of CAR-T Therapies on Clinical, Economic, and Humanistic Outcomes in Patients with Hematological Cancer: A Systematic Literature Review
Doris K. Hansen, Yi-Hsuan Liu, Sandip Ranjan, et al.
Cancers (2023) Vol. 15, Iss. 24, pp. 5746-5746
Open Access | Times Cited: 14
Doris K. Hansen, Yi-Hsuan Liu, Sandip Ranjan, et al.
Cancers (2023) Vol. 15, Iss. 24, pp. 5746-5746
Open Access | Times Cited: 14
Selinexor in multiple myeloma
Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 4, pp. 421-434
Closed Access | Times Cited: 6
Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 4, pp. 421-434
Closed Access | Times Cited: 6
Statins in Mitigating Anticancer Treatment-Related Cardiovascular Disease
Rong Jiang, Lian Lou, Wen Shi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 18, pp. 10177-10177
Open Access | Times Cited: 5
Rong Jiang, Lian Lou, Wen Shi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 18, pp. 10177-10177
Open Access | Times Cited: 5
